Kidney Disease

81-96 of 145

SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
ESC 2021
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
- Prof. Stefan Anker, MD, PhD
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
ESC 2021
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
- Prof. Frank Ruschitzka, MD
Kidney and HF outcomes with SGLT2i across EF spectrum in HF
Kidney and HF outcomes with SGLT2i across EF spectrum in HF
ESC 2021
Kidney and HF outcomes with SGLT2i across EF spectrum in HF
- Prof. Rudolf de Boer
CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD
CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD
ESC 2021
CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD
- Kevin Damman, MD, PhD
Exciting findings of a pooled analysis of two large HF trials with SGLT2i
Exciting findings of a pooled analysis of two large HF trials with SGLT2i
ESC 2021
Exciting findings of a pooled analysis of two large HF trials with SGLT2i
- Milton Packer, MD
Another chapter in the SGLT2i book
Another chapter in the SGLT2i book
ESC 2021
Another chapter in the SGLT2i book
- Prof. Rudolf de Boer
Where do GLP-1RA fit in in current and future management of CKD?
Where do GLP-1RA fit in in current and future management of CKD?
GLP-1RA in DKD: A new preventive challenge
Where do GLP-1RA fit in in current and future management of CKD?
- Frederik Persson, MD
Treatment goals for patients with T2DM and CKD
Treatment goals for patients with T2DM and CKD
SGLT2i in CKD: How to overcome clinical inertia?
Treatment goals for patients with T2DM and CKD
- Prof. Peter Rossing, MD
How can GLP-1RA benefit a patient with diabetes and CKD?
How can GLP-1RA benefit a patient with diabetes and CKD?
GLP-1RA in DKD: A new preventive challenge
How can GLP-1RA benefit a patient with diabetes and CKD?
- Daniël van Raalte, MD, PhD
Practical challenges with SGLT2i therapy in patients with T2DM and CKD
Practical challenges with SGLT2i therapy in patients with T2DM and CKD
SGLT2i in CKD: How to overcome clinical inertia?
Practical challenges with SGLT2i therapy in patients with T2DM and CKD
- Alice Cheng, MD
Prevention strategies in patients with CKD and T2DM
Prevention strategies in patients with CKD and T2DM
GLP-1RA in DKD: A new preventive challenge
Prevention strategies in patients with CKD and T2DM
- Ofri Mosenzon, MD
Clinical inertia in CKD - What is the rationale for SGLT2i?
Clinical inertia in CKD - What is the rationale for SGLT2i?
SGLT2i in CKD: How to overcome clinical inertia?
Clinical inertia in CKD - What is the rationale for SGLT2i?
- Janaka Karalliedde, MD, PhD
Kidney benefit by SGLT2i may be mediated by hematocrit
Kidney benefit by SGLT2i may be mediated by hematocrit
Kidney Disease
Kidney benefit by SGLT2i may be mediated by hematocrit
- Prof. Christoph Wanner
Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction
Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction
Kidney Disease
Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction
- James Januzzi, MD
Effects of iron deficiency on outcomes in HF
Effects of iron deficiency on outcomes in HF
Kidney Disease
Effects of iron deficiency on outcomes in HF
- Adrian F. Hernandez, MD
Concomitant use of diuretics and SGLT2i in HF
Concomitant use of diuretics and SGLT2i in HF
Heart Failure
Concomitant use of diuretics and SGLT2i in HF
- Prof. Patrick Rossignol, MD

6/10

81-96 of 145

Title

Share on ReachMD